María José Calasanz Abinzano-rekin lankidetzan egindako argitalpenak (25)

2024

  1. CALR but Not JAK2 Mutations Are Associated with an Overexpression of Retinoid X Receptor Alpha in Essential Thrombocythemia

    Cancers, Vol. 16, Núm. 8

2013

  1. CBL RING finger deletions are common in core-binding factor acute myeloid leukemias

    Leukemia and Lymphoma

2010

  1. A new potential oncogenic mutation in the FERM domain of JAK2 in BCR/ABL1-negative and V617F-negative chronic myeloproliferative neoplasms revealed by a comprehensive screening of 17 tyrosine kinase coding genes

    Cancer Genetics and Cytogenetics, Vol. 199, Núm. 1, pp. 1-8

  2. Quantification of PDGFRA alternative transcripts improves the screening for XPDGFRA fusions by reverse transcriptase-polymerase chain reaction

    Leukemia and Lymphoma, Vol. 51, Núm. 9, pp. 1720-1726

2008

  1. Low frequency of JAK2 exon 12 mutations in classic and atypical CMPDs

    Leukemia Research

  2. Methylation status of SOCS1 and SOCS3 in BCR-ABL negative and JAK2V617F negative chronic myeloproliferative neoplasms

    Leukemia Research

2006

  1. JAK2 V617F mutation in classic chronic myeloproliferative diseases: A report on a series of 349 patients [10]

    Leukemia

2005

  1. Disruption and aberrant expression of HMGA2 as a consequence of diverse chromosomal translocations in myeloid malignancies

    Leukemia, Vol. 19, Núm. 2, pp. 245-252

  2. Erratum: NUP98 is fused to HOXA9 in a variant complex t(7;11;13;17) in a patient with AML-M2 (Cancer Genetics and Cytogenetics (2005) 157 (151-6))

    Cancer Genetics and Cytogenetics

  3. NUP98 is fused to HOXA9 in a variant complex t(7;11;13;17) in a patient with AML-M2

    Cancer Genetics and Cytogenetics, Vol. 157, Núm. 2, pp. 151-156

2004

  1. Clinical variability of patients with the t(6;8)(q27;p12) and FGFR1OP-FGFR1 fusion: Two further cases

    Hematology Journal, Vol. 5, Núm. 6, pp. 534-537

  2. Cryptic ins(2;11) with clonal evolution showing amplification of 11q23-q25 either on hsr(11) or on dmin, in a patient with AML-M2 [4]

    Leukemia

  3. Cytogenetic profile of myelodysplastic syndromes with complex karyotypes: An analysis using spectral karyotyping

    Cancer Genetics and Cytogenetics, Vol. 153, Núm. 1, pp. 39-47

  4. Molecular heterogeneity in AML/MDS patients with 3q21q26 rearrangements

    Genes Chromosomes and Cancer, Vol. 40, Núm. 3, pp. 179-189

  5. NIN, a Gene Encoding a CEP110-Like Centrosomal Protein, Is Fused to PDGFRB in a Patient with a t(5;14)(q33;q24) and an Imatinib-Responsive Myeloproliferative Disorder

    Cancer Research, Vol. 64, Núm. 8, pp. 2673-2676

  6. Remission of acute monocytic leukemia, secondary to treatment with epipodophyllotoxins, in a patient with t(8;16)(p11;p13) and MYST3-CREBBP fusion [5]

    Cancer Genetics and Cytogenetics

2003

  1. Methylation of CpG dinucleotides and/or CCWGG motifs at the promoter of TP53 correlates with decreased gene expression in a subset of acute lymphoblastic leukemia patients

    Oncogene, Vol. 22, Núm. 7, pp. 1070-1072

  2. NUP98 is fused to Adducin 3 in a patient with T-cell acute lymphoblastic leukemia and myeloid markers, with a new translocation t(10;11)(q25;p15)

    Cancer Research, Vol. 63, Núm. 12, pp. 3079-3083

  3. Novel translocations that disrupt the platelet-derived growth factor receptor β (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders

    British Journal of Haematology, Vol. 120, Núm. 2, pp. 251-256

  4. TP53 Is Frequently Altered by Methylation, Mutation, and/or Deletion in Acute Lymphoblastic Leukaemia

    Molecular Carcinogenesis, Vol. 38, Núm. 4, pp. 201-208